Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

IFNα stimulant

DRUG CLASS:

IFNα stimulant

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive : A1	Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	nadofaragene firadenovec-vncg Sensitive: A1 - Approval nadofaragene firadenovec-vncg Sensitive : A1	nadofaragene firadenovec-vncg Sensitive: A1 - Approval nadofaragene firadenovec-vncg Sensitive : A1
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline bevacizumab + pegylated interferon α -2a Sensitive : A2	bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline bevacizumab + pegylated interferon α -2a Sensitive : A2